Thrombosis
Conference Coverage
Anticoagulants may have advantage over aspirin for low-risk TAVR
NATIONAL HARBOR, MD. – Anticoagulant therapy is found superior to antiplatelet therapy for preventing leaflet thrombosis after TAVR.
Conference Coverage
AUGUSTUS: Apixaban surpassed warfarin despite prior stroke or thromboembolism
LOS ANGELES – Secondary AUGUSTUS analysis showed ACS/PCI patients with AFib plus prior stroke, TIA, or thromboembolism did better on apixaban.
Conference Coverage
AFib patients do best on a DOAC started 7-10 days post stroke
LOS ANGELES – Observational data hints at the best time to start oral anticoagulation in AFib patients after a cardioembolic stroke.
Conference Coverage
After PCI, stopping antiplatelet therapy for surgery appears safe
NATIONAL HARBOR, MD. –
Conference Coverage
TNK dose in large-vessel stroke: 0.25 mg/kg is sufficient
New data from a second EXTEND-IA TNK (tenecteplase) trial clarify the optimum dose of the bolus thrombolytic for use in ischemic stroke.
Conference Coverage
What 2019’s top five CAD trials tell us
SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.
Conference Coverage
Vigilance safely keeps AFib patients off anticoagulants post ablation
NATIONAL HARBOR, MD. – One U.S. center uses frequent monitoring to allow selected AFib patients to safely stop anticoagulation after catheter...
Conference Coverage
Are providers asking about menstrual bleeding before/during anticoagulant therapy?
Conference Coverage
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...